Sigilon Therapeutics is a small company in Boston that, up until this point, has been relatively quiet about their work in the Type 1 diabetes treatment effort. Today, Eli Lilly and Company announced an investment partnership with Sigilon – an upfront payment of $63 million and up to $410 million more as the Sigilon’s research hits development and commercialization milestones.